Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Smart Money Is Betting Big In DHR Options

2024-09-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

October 25th Options Now Available For Danaher (DHR)

2024-09-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Danaher’s Transition to Synergistic Growth and New Capital Strategy: A Hold Rating Analysis

2024-09-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

IN BRIEF: Danaher confirms guidance for third quarter and 2024

2024-09-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Danaher Confirms Third Quarter and Full Year 2024 Guidance

2024-09-04
Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.

Navigating Market Uncertainty: Intrinsic Value of Danaher Corp

2024-09-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Danaher still sees Q3 non-GAAP revenue down in low-single digits year-over-year

2024-09-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Danaher backs FY24 revenue growth down in low-single digits from $23.89B in FY23

2024-09-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Danaher’s Diagnostics Sector Drives Strong Buy Rating Amidst Solid Performance and Diverse Growth Prospects

2024-09-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Is Danaher Corporation (DHR) the Best Cancer Stock to Buy Now?

2024-09-04
We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other cancer stocks. Global Oncology Market Overview and Drug Shortages In 2022, the global oncology market was valued at approximately $203.42 billion and is […]